U.S. FDA looks to pave way for earlier-stage Alzheimer's drugs

(Reuters) - U.S. regulators have proposed lowering the bar for clinical trial success for experimental Alzheimer's drugs to better align with the current emphasis on the need to treat people when they are in the earliest stages of the brain-wasting disease.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news